Clinical Trial Update: Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy of tofacitinib on skin thickening in diffuse cutaneous systemic sclerosis, compared with methotrexate; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Scleroderma
• Systemic Sclerosis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tofacitinib (Xeljanz) (tofacitinib)

Snippet

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Conditions: Scleroderma, Systemic | Phase 4 | Status: COMPLETED